Robert C. Penland

1.2k total citations
38 papers, 853 citations indexed

About

Robert C. Penland is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Robert C. Penland has authored 38 papers receiving a total of 853 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Surgery and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Robert C. Penland's work include Diabetes Treatment and Management (20 papers), Pancreatic function and diabetes (12 papers) and Diabetes Management and Research (10 papers). Robert C. Penland is often cited by papers focused on Diabetes Treatment and Management (20 papers), Pancreatic function and diabetes (12 papers) and Diabetes Management and Research (10 papers). Robert C. Penland collaborates with scholars based in United States, Poland and Sweden. Robert C. Penland's co-authors include Craig S. Henriquez, A.L. Muzikant, Edward W. Hsu, Susan A. Matulevicius, David W. Boulton, David M. Harrild, Gabriel Helmlinger, Weifeng Tang, Lindsay E. Clegg and Hiddo J.L. Heerspink and has published in prestigious journals such as Gastroenterology, Diabetes Care and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Robert C. Penland

33 papers receiving 835 citations

Peers

Robert C. Penland
Barbara Palumbo Italy
Hannah J. Whittington United Kingdom
Masami Goto Japan
Yuka Kikuchi Japan
Amir Ali Rahsepar United States
Xinhua Yan United States
Jin Kyung Kim United States
Eckhard P. Kromer Germany
Tomofumi Takaya Japan
Yasumasa Tsukamoto Japan
Barbara Palumbo Italy
Robert C. Penland
Citations per year, relative to Robert C. Penland Robert C. Penland (= 1×) peers Barbara Palumbo

Countries citing papers authored by Robert C. Penland

Since Specialization
Citations

This map shows the geographic impact of Robert C. Penland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Penland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Penland more than expected).

Fields of papers citing papers by Robert C. Penland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Penland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Penland. The network helps show where Robert C. Penland may publish in the future.

Co-authorship network of co-authors of Robert C. Penland

This figure shows the co-authorship network connecting the top 25 collaborators of Robert C. Penland. A scholar is included among the top collaborators of Robert C. Penland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert C. Penland. Robert C. Penland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Penland, Robert C., et al.. (2025). Model-based Comparison of the Pharmacokinetic/Pharmacodynamic and Eosinophilic Response of Benralizumab Versus Depemokimab at 12 Weeks. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2502–A2502.
2.
Penland, Robert C., Pengfei Liu, I. Jonathan Amster, et al.. (2024). Brown Carbon Emissions from Biomass Burning under Simulated Wildfire and Prescribed-Fire Conditions. ACS ES&T Air. 1(9). 1124–1136. 4 indexed citations
3.
Sokolov, Victor, et al.. (2023). A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT Pharmacometrics & Systems Pharmacology. 12(6). 831–841. 4 indexed citations
4.
Clegg, Lindsay E., Lulu Chu, Mats Någård, David W. Boulton, & Robert C. Penland. (2023). Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study. CPT Pharmacometrics & Systems Pharmacology. 13(2). 296–307. 3 indexed citations
5.
6.
Clegg, Lindsay E., Yankang Jing, Robert C. Penland, et al.. (2021). Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials. Diabetes Obesity and Metabolism. 23(5). 1101–1110. 5 indexed citations
7.
Basu, Sanchita, Weifeng Tang, Robert C. Penland, et al.. (2021). Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. The Journal of Clinical Pharmacology. 62(4). 541–554. 3 indexed citations
8.
Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2020). Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes Obesity and Metabolism. 22(12). 2493–2498. 25 indexed citations
9.
Clegg, Lindsay E., Adrian F. Hernandez, George L. Bakris, et al.. (2020). Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obesity and Metabolism. 22(5). 798–806. 12 indexed citations
10.
Hallow, K. Melissa, David W. Boulton, Robert C. Penland, et al.. (2020). Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeutics. 375(1). 76–91. 10 indexed citations
11.
Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2019). Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology. 18(1). 138–138. 57 indexed citations
12.
13.
Sokolov, Victor, Shinya Ueda, Joanna Parkinson, et al.. (2018). Dapagliflozin Exposure Response in Japanese vs. Non-Japanese Patients with Type 1 Diabetes. Diabetes. 67(Supplement_1). 1 indexed citations
14.
Becker, D. E., Jin Zhang, Tycho Heimbach, et al.. (2014). Novel Orally Swallowable IntelliCap® Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug. AAPS PharmSciTech. 15(6). 1490–1497. 75 indexed citations
15.
Erdemli, Gül, Albert M. Kim, Haisong Ju, et al.. (2012). Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation. Frontiers in Pharmacology. 3. 6–6. 33 indexed citations
16.
Penland, Robert C., Kevin J. Sampson, & Craig S. Henriquez. (2003). Premature beats undergo transmural conduction slowing due to intrinsic APD dispersion. 2. 1189–1189.
17.
Penland, Robert C., et al.. (2002). Using In Silico Biology to Facilitate Drug Development. Novartis Foundation symposium. 247. 222–243. 11 indexed citations
18.
Sachse, Frank B., Craig S. Henriquez, Gunnar Seemann, et al.. (2002). Modeling of fiber orientation in the ventricular myocardium with MR diffusion imaging. 45 2. 617–620. 8 indexed citations
19.
Penland, Robert C., et al.. (2001). Why are cure rates with PPI triple therapy relatively low in the United States?. Gastroenterology. 120(5). A586–A586. 1 indexed citations
20.
Harrild, David M., Robert C. Penland, & Craig S. Henriquez. (2000). A flexible method for simulating cardiac conduction in three-dimensional complex geometries. Journal of Electrocardiology. 33(3). 241–251. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Palumbo Breakdown of academic impact, for papers by Hannah J. Whittington Breakdown of academic impact, for papers by Masami Goto Breakdown of academic impact, for papers by Yuka Kikuchi Breakdown of academic impact, for papers by Amir Ali Rahsepar Breakdown of academic impact, for papers by Xinhua Yan Breakdown of academic impact, for papers by Jin Kyung Kim Breakdown of academic impact, for papers by Eckhard P. Kromer Breakdown of academic impact, for papers by Tomofumi Takaya Breakdown of academic impact, for papers by Yasumasa Tsukamoto
Rankless by CCL
2026